Abstract
Plasma interleukin-1β (IL-1β) concentrations were measured in 10 outpatients with panic disorder before and on days 30 and 32 of treatment with alprazolam (2–2.5 mg/day). IL-1β concentrations were found to be significantly higher in patients than in control subjects both before and during therapy. Thus, IL-1β levels may be a marker of panic disorder that is not related to the current level of symptomatology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
